Pharmaceutical lobbying rose dramatically before the passage of Obamacare, and appears to be rising again, amidst concerns that the government will address rising drug prices.
Pharmaceutical lobbying rose dramatically before the passage of Obamacare, and appears to be rising again, amidst concerns that the government will address rising drug prices.